Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

19.4%

6 terminated/withdrawn out of 31 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

10%

3 trials in Phase 3/4

Results Transparency

47%

7 of 15 completed trials have results

Key Signals

7 recruiting7 with results

Enrollment Performance

Analytics

Phase 2

13(48.1%)

Phase 1

7(25.9%)

N/A

4(14.8%)

Phase 3

2(7.4%)

Phase 4

1(3.7%)

27Total

Phase 2(13)

Phase 1(7)

N/A(4)

Phase 3(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (31)

Showing 20 of 31 trials

NCT05655949Phase 2Recruiting

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

Role: collaborator

NCT04736121Not ApplicableActive Not Recruiting

Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients

Role: lead

NCT07345247Recruiting

RAdiation SEgmentectomy With REsin Microspheres (RASEREM) Study

Role: collaborator

NCT05195710Phase 1Recruiting

Preoperative Y-90 Radioembolization for Tumor Control and Future Liver Remnant Hypertrophy in Patients With Colorectal Liver Metastases

Role: collaborator

NCT05377034Phase 2Recruiting

Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC Patients

Role: collaborator

NCT05701488Phase 1Recruiting

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Role: collaborator

NCT02807181Phase 2Terminated

SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma

Role: lead

NCT06555133Phase 2Recruiting

Y-90, Capecitabine, and Atezolizumab for Oligometastatic CRC

Role: collaborator

NCT05848947Phase 4Completed

SIR-Spheres Study to Calculate the Radiation-Absorbed Dose of 99mTc-MAA

Role: lead

NCT05967143Recruiting

Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry)

Role: lead

NCT05315687Phase 2Withdrawn

Radioembolization of Metastatic Breast Cancer to the Liver as a 2nd/3rd Line Therapy

Role: collaborator

NCT02195011Phase 2Completed

Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases

Role: collaborator

NCT02602327Phase 1Completed

Tas-102 and Radioembolization With 90Y Resin Microspheres for Chemo-refractory Colorectal Liver Metastases

Role: collaborator

NCT01098422Not ApplicableTerminated

A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver

Role: collaborator

NCT00503867Not ApplicableTerminated

SIR-Spheres® for the Treatment of Unresectable Hepatocellular Carcinoma

Role: lead

NCT03380130Phase 2Completed

A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCC

Role: collaborator

NCT01721954Phase 3Completed

FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer

Role: lead

NCT01126645Phase 2Completed

Sorafenib and Micro-therapy Guided by Primovist Enhanced MRI in Patients With Inoperable Liver Cancer

Role: collaborator

NCT00724503Not ApplicableCompleted

FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets From Primary Colorectal Cancer

Role: lead

NCT02416466Phase 1Completed

CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases

Role: collaborator